Please try another search
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
Name | Age | Since | Title |
---|---|---|---|
James Wakefield | - | 2014 | Independent Non-Executive Chairman of the Board |
James Martin McCarthy | 58 | 2021 | Acting CEO & Director |
David Gardner | - | - | Member of Scientific Committee |
Andrew John William Heath | 76 | 2015 | Independent Senior Non-Executive Director |
Juliet Thompson | 58 | 2017 | Independent Non-Executive Director |
Jean-Pierre Crinelli | - | - | Independent Non-Executive Director |
Marco Zonta | - | - | Member of Scientific Committee |
Isabelle Cartier | - | - | Member of Scientific Committee |
Geneviève Bourg-Heckly | - | - | Member of Scientific Committee |
Steve Gibson | - | 2017 | CFO & Director |
Lyn Dafydd Rees | 51 | 2023 | Executive Director |
John Robert Brown | 69 | 2023 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review